183 filings
Page 6 of 10
8-K
7jcqo4
3 Oct 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:09pm
8-K
y01wfh5dwcvw ua
20 Sep 19
KemPharm Provides Updates Regarding its Board of Directors
5:07pm
8-K
i0nd6697 rz
4 Sep 19
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales
8:01am
8-K
9rjr99
13 Aug 19
KemPharm Reports Second Quarter 2019 Results
5:06pm
8-K
kvmwbyg
23 May 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:21pm
8-K
cu9 br7uw
14 May 19
KemPharm Reports First Quarter 2019 Results
4:10pm
8-K
str1ixb
26 Apr 19
Submission of Matters to a Vote of Security Holders
4:54pm
8-K
6t60yjlb
11 Apr 19
KemPharm Completes KP415 Pre-NDA Meeting with FDA
4:59pm
8-K
kwi7og msldkucm
13 Mar 19
KemPharm Provides Update on APADAZ® Formulary Adoption
7:38am
8-K
bugelrik8f 8c08fr
28 Feb 19
KemPharm Reports Q4 and FY 2018 Results
12:00am
8-K
hj8tz27fu2bthkcvv
7 Jan 19
Regulation FD Disclosure
9:18am
8-K
sfz943xb5
19 Dec 18
KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio
7:36am
8-K
tof0oxg
6 Dec 18
Regulation FD Disclosure
9:24am
8-K
vcpwds
20 Nov 18
Entry into a Material Definitive Agreement
5:17pm
8-K
ms0tnpqvw2zlc0gzhxo
8 Nov 18
KemPharm, Inc. Reports Third Quarter 2018 Results
4:12pm
8-K
j4p51lo7pj
30 Oct 18
Entry into a Material Definitive Agreement
4:07pm
8-K
ney7nsw
5 Oct 18
KemPharm Announces Pricing of Public Offering of Common Stock
10:03am
8-K
9mfdz frcqg
4 Oct 18
KemPharm Announces Proposed Public Offering of Common Stock
5:27pm
8-K
ipbl 8knssrwxb
17 Sep 18
Regulation FD Disclosure
12:00am
8-K
7gobavg7
4 Sep 18
Entry into a Material Definitive Agreement
12:00am